Zurzuvae (drug named: Zuranolone) was just approved by the U.S. Food and Drug Administration (FDA) as the first oral medication indicated to treat postpartum depression. Postpartum depression typically occurs after childbirth, but can also occur during the later stages of pregnancy. Watch here for the mechanism of how Zurzuvae works to mimic allopregnanolone levels in the body.